Suppr超能文献

氨苄西林和庆大霉素治疗早发型新生儿败血症:一种方法并不适用于所有情况。

Ampicillin and Gentamicin Treatment for Early Onset Neonatal Sepsis: When One Size Does Not Fit All.

机构信息

University of California, Los Angeles, CA, USA.

Pediatric Infectious Diseases, CHOC Children's Hospital, Orange, CA, USA.

出版信息

Clin Pediatr (Phila). 2023 Oct;62(9):1027-1031. doi: 10.1177/00099228221150612. Epub 2023 Jan 24.

Abstract

Based on in vitro susceptibilities and the concern for emergence of resistance and long-term safety, ampicillin plus gentamicin remains the recommended antibiotic regimen for early onset neonatal sepsis. Our objective was to identify potential limitations of this regimen based on clinical and pathogen characteristics while minimizing risks associated with prolonged antibiotic exposure. We identified 43 gram-negative pathogens in 42 patients. () occurred in 50% and in 23.8% of patient. Ampicillin resistance was common, particularly in (85.7%). Mortality was 23.8%, all due to . We found that is the most frequent pathogen and has a high mortality particularly in neonates < 1500 g; mortality is high with the current dosing strategy when is resistant to ampicillin even when sensitive to gentamicin; resistance to gentamicin remains low but seems to be increasing while resistance to third-generation cephalosporins remains very low.

摘要

基于体外药敏结果以及对耐药性出现和长期安全性的考虑,氨苄西林联合庆大霉素仍然是新生儿早发性败血症的推荐治疗方案。我们的目的是在尽量减少与延长抗生素暴露相关风险的同时,根据临床和病原体特征,确定该方案的潜在局限性。我们在 42 名患者中鉴定出 43 种革兰氏阴性病原体。()在 50%和()在 23.8%的患者中发生。氨苄西林耐药很常见,尤其是(85.7%)。死亡率为 23.8%,均归因于()。我们发现()是最常见的病原体,尤其是在体重<1500 克的新生儿中,死亡率很高;当对氨苄西林耐药而对庆大霉素敏感时,即使按照目前的剂量方案,死亡率也很高;庆大霉素耐药率仍然较低,但似乎在增加,而第三代头孢菌素的耐药率仍然非常低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验